High Growth Tech Stocks To Watch In US July 2025

The United States market has been flat over the last week but is up 13% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high-growth tech stocks can be crucial for investors seeking opportunities that align with these promising growth forecasts.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 227 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Incyte (INCY)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Incyte Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics across the United States, Europe, Canada, and Japan with a market cap of $13.30 billion.

Operations: Incyte generates revenue primarily from its biotechnology segment, amounting to $4.41 billion.

Incyte's recent leadership changes and strategic filings suggest a proactive approach in bolstering its market position. With the appointment of Bill Meury as CEO, known for his robust commercial strategy and R&D integration at Anthos Therapeutics and Karuna Therapeutics, Incyte is poised to enhance its operational dynamics. The company's recent shelf registration of $68.73 million potentially gears towards funding these expansive strategies. Moreover, the FDA's extended review period for Incyte’s Opzelura cream underlines a commitment to thorough developmental processes, aiming to solidify its footprint in dermatological treatments. These maneuvers reflect a strategic alignment designed to fortify Incyte’s presence in competitive biotech landscapes, leveraging seasoned leadership and regulatory engagements to potentially accelerate growth trajectories.

• Navigate through the intricacies of Incyte with our comprehensive health report here.

• Evaluate Incyte's historical performance by accessing our past performance report.

Madrigal Pharmaceuticals (MDGL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH) in the United States, with a market cap of $6.85 billion.

Operations: Madrigal Pharmaceuticals focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the U.S., with a market cap of $6.85 billion.

Madrigal Pharmaceuticals has been making significant strides in the treatment of MASH, a rapidly growing cause of liver transplants in Europe. Their drug, Rezdiffra, stands out as the first FDA-approved medication for MASH with moderate to advanced fibrosis and has shown promising results in improving fibrosis and resolving MASH in clinical trials. The recent positive opinion from CHMP could pave the way for European approval, enhancing Madrigal's market presence. With R&D expenses at $28.272 million, reflecting their commitment to innovation and targeted therapies, Madrigal is poised to meet urgent medical needs while expanding its footprint in the biopharmaceutical sector.

• Click here and access our complete health analysis report to understand the dynamics of Madrigal Pharmaceuticals.

• Gain insights into Madrigal Pharmaceuticals' historical performance by reviewing our past performance report.

Scholar Rock Holding (SRRK)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Scholar Rock Holding Corporation is a biopharmaceutical company dedicated to discovering, developing, and delivering medicines targeting serious diseases influenced by protein growth factor signaling, with a market cap of $3.51 billion.

Operations: Scholar Rock Holding Corporation focuses on developing innovative treatments for diseases influenced by protein growth factor signaling. The company operates within the biopharmaceutical sector, leveraging its expertise to advance its pipeline of therapeutic candidates.

Despite recent setbacks, including its removal from several Russell indices, Scholar Rock Holding remains a compelling narrative in the biotech landscape. The company's focus on developing apitegromab—a potential game-changer for spinal muscular atrophy—underscores its innovative edge. With R&D expenses reflecting significant investment in groundbreaking therapies, Scholar Rock is not just chasing trends but potentially setting them. Its revenue growth forecast at an impressive 55.1% annually outpaces the broader U.S market's 8.8%, highlighting its aggressive expansion trajectory despite current unprofitability and market challenges.

• Delve into the full analysis health report here for a deeper understanding of Scholar Rock Holding.

• Examine Scholar Rock Holding's past performance report to understand how it has performed in the past.

Where To Now?

• Navigate through the entire inventory of 227 US High Growth Tech and AI Stocks here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com